How long has lorlatinib/lorlatinib been available in China?

Lorlatinib/Lorlatinib (Lorlatinib) is an oral tyrosine kinase inhibitor targeting ALK and ROS1 fusion-positive non-small cell lung cancer (NSCLC). As a third-generation ALK inhibitor, it can cross the blood-brain barrier and has a targeted inhibitory effect on central nervous system metastasis, making it an important part of the treatment sequence for patients with ALK fusion-positive lung cancer. Compared with early first- and second-generation ALK inhibitors, lorlatinib also shows strong inhibitory ability against multiple drug-resistant mutations, so it has received great attention globally.

In China, lorlatinib will be approved for marketing in April 2022. The National Medical Products Administration (NMPA) approved lorlatinib tablets for the treatment of patients with locally advanced or metastatic ALK-positive non-small cell lung cancer who have progressed after previously receiving ALK inhibitor therapy. The domestic product name is "Borina" and the original drug is called lorlatinib tablets. This time to market is slightly behind that of some developed countries, but it is of great significance to Chinese ALK fusion-positive patients, which means that they can obtain this breakthrough precision targeted therapy drug locally without having to rely entirely on overseas imports.

The launch of lorlatinib also marks a key step in China's introduction and localization of high-end targeted drugs. With the entry of Borina into the market, clinical use of the drug has gradually begun across the country. More patients who have lost first-line or second-line treatment options due to disease progression can delay the progression of their disease through new targeted drugs. Furthermore, Borina has been included in China’s Class B medical insurance reimbursement catalog. This policy change greatly reduces the financial burden on patients. From the perspective of medical insurance reimbursement, the Category B catalog usually reimburses a certain percentage of drug costs, whether in the drug purchase settlement of public hospitals or through the social medical insurance payment system. This inclusion means that lorlatinib has become accessible to a wider patient group.

Keyword tags: lorlatinib Launched China Time 2022 ALK inhibitor Borina non-small cell lung cancer Class B medical insurance reimbursement specifications

Reference materials：https://www.lorbrena.com/